ENGN enGene Holdings Inc. - Common Stock
$1.75
Price · Aug 19, 2026
Fundamentals as of Mar 11, 2024
52W Range
$1–$12
3% of range
Analyst Rating
HOLD
18 analysts
Price Target
$3
+88% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
ENGN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$1.75
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$1 – $12
ENGN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
ENGN
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
ENGN
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
ENGN
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
ENGN
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
ENGN
Peer Median
ENGN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
18 analysts
- Strong Buy 4 22.2%
- Buy 6 33.3%
- Hold 7 38.9%
- Sell 1 5.6%
- Strong Sell 0 0.0%
12-Month Price Target
7 analysts · 2026-08-18
Median
$4.00
Mean
$3.29
← Below all targets
$1.75
Low
$2.00
High
$5.00
Median target
$4.00
+128.6%
Mean target
$3.29
+87.8%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.01%
Next Report
Sep 09, 2026
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.43 | $-0.48 | 0.05% |
| March 31, 2026 | $-0.44 | $-0.57 | 0.13% |
| Dec. 31, 2025 | $-0.73 | $-0.58 | -0.15% |
| Sept. 30, 2025 | $-0.57 | $-0.51 | -0.06% |
| June 30, 2025 | $-0.51 | $-0.51 | -0.00% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ENGN | — | — | — | — | — | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
| PMN | $15M | -0.3 | — | — | 4840.3% | — |
| EDSA | $18M | — | — | — | -51.3% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 14
| Metric | Trend | Q4 2024 | Q4 2023 |
|---|---|---|---|
| R&D Expense | $6M | $4M | |
| SG&A Expense | $5M | $962.0K | |
| Operating Expenses | $11M | $5M | |
| Operating Income | $-11M | $-5M | |
| Interest Expense | $563.0K | $1M | |
| Interest Income | $1M | $167.0K | |
| Other Non-op | $-64.0K | $-285.0K | |
| Pretax Income | $-11M | $-7M | |
| Income Tax | $-30.0K | $0 | |
| Net Income | $-11M | $-7M | |
| EPS (Basic) | $0.46 | $13.29 | |
| EPS (Diluted) | $0.46 | $13.29 | |
| Shares (Basic) | 23,197,976 | 651,074 | |
| Shares (Diluted) | 23,197,976 | 651,074 |
Balance Sheet 18
| Metric | Trend | Q4 2024 | Q4 2023 |
|---|---|---|---|
| Cash & Equivalents | $86M | · | |
| Prepaid Expense | $3M | · | |
| Current Assets | $90M | · | |
| PP&E (Net) | $993.0K | · | |
| PP&E (Gross) | $3M | · | |
| Accum. Depreciation | $2M | · | |
| Other Non-current Assets | $974.0K | · | |
| Total Assets | $93M | · | |
| Accounts Payable | $1M | · | |
| Current Liabilities | $7M | · | |
| Capital Leases | $2M | · | |
| Total Liabilities | $31M | · | |
| Common Stock | $259M | · | |
| Retained Earnings | $-210M | · | |
| AOCI | $-1M | · | |
| Stockholders' Equity | $62M | · | |
| Liabilities + Equity | $93M | · | |
| Shares Outstanding | 23,197,976 | · |
Cash Flow 7
| Metric | Trend | Q4 2024 | Q4 2023 |
|---|---|---|---|
| D&A | $80.0K | $46.0K | |
| Stock-based Comp | $291.0K | $20.0K | |
| Operating Cash Flow | $-7M | $-6M | |
| CapEx | $506.0K | $13.0K | |
| Investing Cash Flow | $-506.0K | $-13.0K | |
| Financing Cash Flow | $12M | $-10.0K | |
| Net Change in Cash | $4M | $-6M |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 6 filers · $15.1M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 1 | 54 | 1 | 0 | — |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FCPM III SERVICES B.V. | $11,657,366 | 6,738,362 | 77.39% | Shares |
| Omega Fund Management, LLC | $1,516,098 | 876,357 | 10.07% | Shares |
| SR One Capital Management, LP | $1,293,607 | 747,750 | 8.59% | Shares |
| Quadrature Capital Ltd | $413,531 | 239,035 | 2.75% | Shares |
| TWO SIGMA ADVISERS, LP | $156,219 | 17,300 | 1.04% | Shares |
| OBSIDIAN CIO, LLC | $25,950 | 15,000 | 0.17% | Shares |
Company insiders 25 insiders · 14 officers · 11 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ronald Harold Wilfred Cooper | CEO & President | Jan. 30, 2026 A | 10,000 | 0 | 0 | $0 |
| Jason David Hanson | Chief Executive Officer | July 7, 2023 A | — | 0 | 0 | $0 |
| Ryan D. Daws | Chief Financial Officer | Jan. 30, 2026 A | — | 0 | 0 | $0 |
| Matthew Ross Boyd | Chief Regulatory Officer | Jan. 30, 2026 A | — | 0 | 0 | $0 |
| Joan Connolly | Chief Technology Officer | Jan. 30, 2026 A | — | 0 | 0 | $0 |
| Alexander Julian Nichols | Chief Strategy & Ops. Ofc | Jan. 30, 2026 A | — | 0 | 0 | $0 |
| Anthony Tzeyew Cheung | Chief Scientific Officer | Jan. 30, 2026 A | 102,873 | 0 | 0 | $0 |
| Lee Giguere | Chief Legal Ofc. and Corp Secy | Jan. 30, 2026 A | — | 0 | 0 | $0 |
| Jill Buck | Chief Development Officer | Jan. 30, 2026 A | — | 0 | 0 | $0 |
| Hussein Sweiti | Chief Medical Officer | Sept. 30, 2025 A | — | 0 | 0 | $0 |
| Amy Pott | Chief Global Comm. Ofc. | June 16, 2025 A | — | 0 | 0 | $0 |
| Raj Som Pruthi | Chief Medical Officer | Jan. 29, 2025 A | — | 0 | 0 | $0 |
| Richard Paul Bryce | Chief Medical Officer | Nov. 30, 2023 A | — | 0 | 0 | $0 |
| James Crowley Sullivan | Chief Scientific Officer | July 7, 2023 A | — | 0 | 0 | $0 |
| William Grossman | Director | July 8, 2025 A | — | 0 | 0 | $0 |
| Michael Thomas Heffernan | Director | July 8, 2025 A | — | 0 | 0 | $0 |
| Philip Astley-Sparke | Director | July 8, 2025 A | — | 0 | 0 | $0 |
| Wouter Joustra | Director | June 16, 2025 A | — | 0 | 0 | $0 |
| Jasper Bos | Director | June 16, 2025 A | — | 0 | 0 | $0 |
| Gerald A Brunk | Director | June 16, 2025 A | 238,851 | 0 | 0 | $0 |
| Richard M Glickman | Director | June 16, 2025 A | 24,675 | 0 | 0 | $0 |
| Paul J Hastings | Director | June 16, 2025 A | — | 0 | 0 | $0 |
| Lota S. Zoth | Director | June 16, 2025 A | — | 0 | 0 | $0 |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10% owner | April 22, 2024 S | 3,036,153 | 0 | 0 | $0 |
| Lumira Capital Investment Management Inc. | 10% owner | Feb. 20, 2024 A | 238,851 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Forbion Growth Sponsor FEAC I B.V., Forbion Growth Opportunities Fund I Cooperatief U.A., Forbion Growth Management B.V. ×2 filings | Nov. 1, 2024 | — | Initial filing | — | SEC |
| Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck Lumira Biosciences Fund, L.P., Merck Lumira Biosciences Fund (Québec), L.P., Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc., Peter van der Velden, Benjamin Rovinski, Daniel Hetu, Gerald Brunk, Vasco Larcina, Jacki Jenuth ×2 filings | Feb. 21, 2024 | — | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.